返回 
加入收藏
多西他赛联合替吉奥对晚期胃癌患者CEA、CA199、TAM水平及疗效的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 多西他赛联合替吉奥对晚期胃癌患者CEA、CA199、TAM水平及疗效的影响 |
| TITLE： | |
| 摘要： | 目的：探讨多西他赛联合替吉奥对晚期胃癌患者癌胚抗原（CEA）、糖类抗原199（CA199）、肿瘤相关物质（TAM）水平及疗效的影响。方法：选取2016年1月－2017年8月宜兴市肿瘤医院收治的晚期胃癌患者69例，按治疗方法的不同分为A组（35例）和B组（34例）。A组患者给予多西他赛注射液75 mg/m2，每周1次+替吉奥胶囊，按体表面积给药，每天2次，第1～14天；B组患者给予注射用顺铂20 mg/m2，每天1次，第1～5天+替吉奥胶囊（用法用量同A组）。两组均以用药3周、间隔1周为1个疗程，连续治疗4个疗程。观察两组患者治疗前后血浆CEA、CA199、TAM水平，记录其临床疗效及不良反应发生情况。结果：治疗前，两组患者血浆CEA、CA199、TAM水平比较，差异均无统计学意义（P＞0.05）；治疗后，两组患者上述指标水平均显著降低，且A组显著低于B组，差异均有统计学意义（P＜0.05）。A组患者的总有效率为85.71％，显著高于B组的64.71％，差异有统计学意义（P＜0.05）。两组患者Ⅰ～Ⅳ级血小板减少、贫血、中性粒细胞减少、肝功能损害、腹泻、脱发的发生率比较，差异均无统计学意义（P＞0.05）。结论：与顺铂联合替吉奥化疗方案相比，多西他赛联合替吉奥化疗方案能更好地降低晚期胃癌患者体内CEA、CA199、TAM等肿瘤标志物水平，且化疗效果更佳，同时并未增加不良反应的发生。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of docetaxel combined with tiggio on the levels of carcinoembryonic antigen （CEA）， carbohydrate antigen 199 （CA199） and tumor associated material （TAM）， therapeutic efficacy in patients with advanced gastric cancer. METHODS： Totally 69 patients with advanced gastric cancer who were admitted to Yixing Tumor Hospital from Jan. 2016 to Aug. 2017 were divided into group A （35 cases） and group B （34 cases） according to treatment plan. Group A was given Docetaxel injection 75 mg/m2， once a week+Tiggio capsules， according to body surface area， twice a day， during first day-fourteenth day. Group B was given Cisplatin for injection 20 mg/m2， once a day， during first day-fifth day+Tiggio capsules（same dosage and usage as group A）. A treatment course lasted for 3 weeks of medication and 1 week of interval. Both groups were treated for consecutive 4 courses. The plasma levels of CEA， CA199 and TAM in 2 groups were observed before and after treatment. Clinical efficacies and the occurrence of ADR were recorded in 2 groups. RESULTS： Before treatment， there was no statistical significance in plasma levels of CEA， CA199 or TAM between 2 groups （P＞0.05）. After treatment， the levels of above indexes in 2 groups were decreased significantly， and group A was significantly lower than group B， with statistical significance （P＜0.05）. Total response rate of group A was 85.71％， which was significantly higher than 64.71％ of group B， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of Ⅰ-Ⅳ degree thrombocytopenia， anemia， neutropenia， liver damage， diarrhea or alopecia between 2 groups （P＞0.05）. CONCLUSIONS： Compared with cisplatin combined with tiggio therapy plan， the chemotherapy regimen of docetaxel combined with tiggio can reduce the levels of tumor markers as CEA， CA199 and TAM with satisfactory therapy efficacy， but cannot increase the occurrence of ADR. |
| 期刊： | 2018年第29卷第18期 |
| 作者： | 吴周姜丽，宗欣，王达飞，陈胜东，许益芬，龚伟达 |
| AUTHORS： | WU Zhoujiangli，ZONG Xin，WANG Dafei，CHEN Shengdong，XU Yifen，GONG Weida |
| 关键字： | 多西他赛；替吉奥；晚期胃癌；癌胚抗原；糖类抗原199；肿瘤相关物质；疗效；安全性 |
| KEYWORDS： | Docetaxel； Tiggio； Advanced gastric cancer； Carcinoembryonic antigen； Carbohydrate antigen 199； Tumor associated material； Therapeutic efficacy； Safety |
| 阅读数： | 570 次 |
| 本月下载数： | 5 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
